Johnson & Johnson has officially completed its acquisition of Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company known for its innovative cancer-targeting technology, in a deal valued at USD 3.05 billion in cash.
The acquisition brings Halda’s proprietary Regulated Induced Proximity Targeting Chimera (RIPTAC™) platform into J&J’s growing oncology portfolio. This novel technology enables the development of targeted, once-daily oral therapies designed to selectively eliminate cancer cells while sparing healthy tissue — a major step forward in precision cancer treatment.
Central to the deal is Halda’s lead clinical-stage candidate, HLD-0915, currently being evaluated for metastatic castration-resistant prostate cancer. This asset is part of a broader pipeline that includes earlier-stage programs for breast, lung, and other solid tumors, reinforcing J&J’s commitment to expanding its presence in hard-to-treat cancers.
Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine at Johnson & Johnson, emphasized that the acquisition represents a strategic milestone in the company’s efforts to “redefine cancer treatment with breakthrough science and transformative medicines.” J&J also noted that the integration of Halda’s research team will help fuel further discovery across oncology and beyond.
The deal underscores Johnson & Johnson’s focus on innovation in oncology, building on nearly two decades of work in prostate cancer and expanding into next-generation precision therapies designed to overcome treatment resistance and improve patient outcomes.
